Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2016
Pharma News, 2016
Will Trump’s election make pharma M&A great again?
Good news, biopharma companies.
Haiti launches massive cholera vaccination drive but worries remain
Haiti has launched a massive cholera vaccination campaign to battle a flare-up after Hurricane Matthew, but concerns remain about the capacity for longer-term improvements to water and sanitation infr...
Valeant may seek to clean up its name by changing it: Ackman
Valeant Pharmaceuticals International Plc (VRX.
Mylan profit misses estimates as EpiPen sales decline
Mylan's third-quarter profit missed analysts' estimates as the drugmaker sold fewer EpiPen emergency allergy shots ahead of a cheaper version of the product that could be launched before next ...
AstraZeneca profit up 32% on year on tax gain
AstraZeneca PLC was boosted by a one-off tax windfall in the third quarter, helping offset heavy investment into the drugs it hopes will fuel strong growth.
Exclusive: Pfizer weighs sale or spin-off of consumer health unit - sources
U.
Work on another Sanofi drug delayed by manufacturing issues
It turns out that the FDA complete response letter (CRL) Sanofi and partner Regeneron recently received for their experimental IL-6 inhibitor, and Humira competitor, sarilumab is not the only ...
Pfizer to close two manufacturing sites in UK with 370 job losses
US drugs giant Pfizer will shut two of its three manufacturing plants in the UK in the next four years, putting 370 jobs at risk.
With Prop 61's defeat, drug-pricing foes can forget state-level action
California has been ground zero in the industry battle against state drug pricing laws, and by a safe margin Tuesday, pharma came out ahead on the contentious Prop 61.
Discovery of Cerecor Drug Candidate CERC-611 (LY3130481) Published in Nature Medicine
BALTIMORE, MD, USA I November 8, 2016 I Cerecor, Inc.
Memantine plus sertraline effective for major depressive disorder
HealthDay News — The combination of memantine plus sertraline is efficacious for major depressive disorder, according to a study published in the Journal of Clinical Pharmacy and Therapeutics.
Ketofol an alternative deep sedative
Australian emergency medicine researchers have successfully trialled an alternative deep sedative for patients in the emergency department.
4
5
6
7
8
9
10
11
12
